Elan: Tysabri suitable for treatment of Crohn's

ISEQ-listed drug company Elan says that its Tysabri drug, which was taken off the market for a time in 2004, is effective in maintaining remission in Crohn’s Disease patients treated for longer than two years.

According to a study, 86% of patients who were in remission after 12 months of treatment were still in remission a year later.